Metastatic Breast Cancer: The Odyssey of Personalization

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2016 Jul 20

PMID 27430154

Citations 12

Authors

A Sonnenblick

N Ponde

M Piccart

Affiliations

Soon will be listed here.

Abstract

Metastatic breast cancer is the most frequent cause of cancer death for women worldwide. In the last 15 years, a large number of new agents have entered clinical use, a result of the dramatic increase in our understanding of the molecular underpinnings of metastatic breast cancer. However, while these agents have led to better outcomes, they are also at the root cause of increasing financial pressure on healthcare systems. Moreover, decision making in an era where every year new agents are added to the therapeutic armamentarium has also become a significant challenge for medical oncologists. In the present article, we will provide an ample review on the most recent developments in the field of treatment of the different subtypes of metastatic breast cancer with a critical discussion on the slow progress made in identifying response biomarkers. New hopes in the form of ctDNA monitoring and functional imaging will be presented.

Citing Articles

EccDNA-oriented expression in breast cancer.

Yang L, Wang M, Hu X, Yuan L, Chen S, Peng S Ann Transl Med. 2023; 10(24):1344.

PMID: 36660685 PMC: 9843317. DOI: 10.21037/atm-22-5716.

The genomic landscape of metastasis in treatment-naïve breast cancer models.

Ross C, Szczepanek K, Lee M, Yang H, Qiu T, Sanford J PLoS Genet. 2020; 16(5):e1008743.

PMID: 32463822 PMC: 7282675. DOI: 10.1371/journal.pgen.1008743.

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Ponde N, Aftimos P, Piccart M Curr Treat Options Oncol. 2019; 20(5):37.

PMID: 30931493 DOI: 10.1007/s11864-019-0633-6.

miR-140-3p inhibits breast cancer proliferation and migration by directly regulating the expression of tripartite motif 28.

Zhou Y, Wang B, Wang Y, Chen G, Lian Q, Wang H Oncol Lett. 2019; 17(4):3835-3841.

PMID: 30881504 PMC: 6403497. DOI: 10.3892/ol.2019.10038.

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.

Toss A, Piacentini F, Cortesi L, Artuso L, Bernardis I, Parenti S Oncotarget. 2018; 9(60):31606-31619.

PMID: 30167082 PMC: 6114971. DOI: 10.18632/oncotarget.25810.

References

Pantel K, Speicher M . The biology of circulating tumor cells. Oncogene. 2015; 35(10):1216-24. DOI: 10.1038/onc.2015.192. View

Mauri D, Pavlidis N, Polyzos N, Ioannidis J . Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006; 98(18):1285-91. DOI: 10.1093/jnci/djj357. View

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

Lee H, Seo A, Kim E, Jang M, Kim Y, Kim J . Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer. 2014; 112(1):103-11. PMC: 4453607. DOI: 10.1038/bjc.2014.556. View

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E . Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014; 32(25):2794-803. DOI: 10.1200/JCO.2013.54.1870. View

Klijn J, Blamey R, Boccardo F, Tominaga T, Duchateau L, Sylvester R . Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001; 19(2):343-53. DOI: 10.1200/JCO.2001.19.2.343. View

McKee M, Keith K, Deal A, Garrett A, Wheless A, Green R . A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. Oncologist. 2015; 21(1):16-20. PMC: 4709216. DOI: 10.1634/theoncologist.2015-0328. View

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

10.

Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1):97-100. DOI: 10.1038/clpt.2009.68. View

11.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

12.

Jamdade V, Sethi N, Mundhe N, Kumar P, Lahkar M, Sinha N . Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015; 172(17):4228-37. PMC: 4556464. DOI: 10.1111/bph.13211. View

13.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Koehler M . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7):1124-30. DOI: 10.1200/JCO.2008.21.4437. View

14.

Reynders K, Illidge T, Siva S, Chang J, De Ruysscher D . The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015; 41(6):503-10. PMC: 4816218. DOI: 10.1016/j.ctrv.2015.03.011. View

15.

Shen Q, Sahin A, Hess K, Suki D, Aldape K, Sawaya R . Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015; 20(5):466-73. PMC: 4425375. DOI: 10.1634/theoncologist.2014-0107. View

16.

Mortimer J, Dehdashti F, Siegel B, Katzenellenbogen J, Fracasso P, Welch M . Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996; 2(6):933-9. View

17.

Treasure T . Oligometastatic cancer: an entity, a useful concept, or a therapeutic opportunity?. J R Soc Med. 2012; 105(6):242-6. PMC: 3380228. DOI: 10.1258/jrsm.2011.110279. View

18.

Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V . Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014; 15(3):267-74. DOI: 10.1016/S1470-2045(13)70611-9. View

19.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F . ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014; 25(10):1871-1888. PMC: 4176456. DOI: 10.1093/annonc/mdu385. View

20.

Lee J, Loh K, Yap Y . PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2016; 12(4):342-54. PMC: 4706528. DOI: 10.7497/j.issn.2095-3941.2015.0089. View